Project cooperationUpdated on 22 December 2025
Start-up developing postbiotics solutions for cardiometabolic conditions
R&D Manager at GENBIOMA
Pamplona, Spain
About
At Genbioma, we are revolutionizing metabolic health with microbiome-based solutions designed for the nutraceutical and food industries. We are pioneers in developing pA1c®HI, the first clinically validated postbiotic for glucose control—a natural, safe, and extremely stable ingredient that is transforming the market.
pA1c®HI offers a unique combination of proven efficacy, complete thermal stability (UHT, pasteurization), and versatile formulation, making it the ideal choice for advanced supplements and functional foods. Its clinical evidence in prediabetes, type 2 diabetes, and obesity positions it as a standout ingredient for brands seeking to innovate with high-impact solutions for consumers.
Thanks to our proprietary development platform and an international network of industrial partners, we accelerate the market launch of disruptive functional ingredients.
We are interested in taking part in projects contributing with our biotic products (nutraceuticals) for improving cardiometabolic health (e.g. type 2 diabetes, hypercholesterolemia).
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
Postbitic for glycemic control (type 2 diabetes, prediabetes)
Angela Moncada Pazos
R&D Manager at GENBIOMA
Pamplona, Spain
Project cooperation
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
- DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
MARTA SANS VALLS
European Programme Manager at Fundacio Eurecat
Barcelona, Spain
Project cooperation
Scaling Up Innovation in Cardiovascular Health
- Consortium/Coordinator seeks Partners
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
Marta Marcoartu
European Affairs at Venus Roses Lab Solutions Ltd.
Brussels, Belgium